The use of the MAGE-A3 immunotherapeutic for use in NSCLC has stopped because of the findings showing no differences between MAGE-A3 immunotherapeutic in comparison to placebo (Table 2). This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.